Altre lingue LianBio

Azioni

Tempo differito OTC Markets Altri mercati azionari 20:02:11 05/07/2024			Variaz. 5gg	Var. 1 gen.
0,31 ^USD	+1,64%		-1,59%	-93,06%

10/05	La cinese Zeekr prezza l'IPO statunitense al massimo della gamma per raccogliere 441 milioni di dollari	RE
07/05	L'unità EV di Geely, Zeekr, punta a raccogliere fino a 367,5 milioni di dollari dall'IPO al NYSE	MT

China's Zeekr prices US IPO at top of range to raise $441 million	10/05
Geely's EV Unit Zeekr Targets Up to $367.5 Million From NYSE IPO	07/05
LianBio(OTCPK:LIAN.Y) dropped from NASDAQ Composite Index	18/03
ADRs End Lower; Akso Health Group Declines 23%	15/03
LianBio Announces Voluntarily Delisting from Nasdaq	28/02
LianBio to Start Winding Down Operations; Complete Dissolution Expected in 2027	13/02
LianBio Announces Completion of Strategic Review	13/02
LianBio Announces Completion of Strategic Review	13/02
Nanobiotix : transfert de droits sur NBTXR3 en Asie	27/12
Nanobiotix Partner Transfers Asian Commercialization Rights for Oncology Therapy to Johnson & Johnson Unit	27/12
Sector Update: Health Care Stocks Mixed Premarket Tuesday	26/12
LianBio Assigns Rights to Nanobiotix's Oncology Therapy in China, Other Asian Markets to Janssen Pharmaceutica	26/12
LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets	26/12
LianBio Enters into Agreement with Janssen Pharmaceutica to Assign its Rights for NBTXR3 in China and Other Asian Markets	26/12
LianBio Finance Chief Resigns, Names Interim CFO	20/12
Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading	20/12
LianBio Announces Departure of Chief Financial Officer	20/12
LianBio Announces Chief Financial Officer Changes	20/12
LianBio CEO Yizhe Wang Resigns; Board Member Adam Stone Named in Interim	19/12
Lianbio Announces Resignation of Yizhe Wang as Member of the Board of Directors	19/12

Non ci sono risultati per questa ricerca